Abrocitinib, tralokinumab or upadacitinib for treating moderate to severe atopic dermatitis

Supporting evidence

• Evaluation report

• Appraisal consultation committee papers (PDF 15.53 MB)

  Published:

  03 August 2022

• Final appraisal determination committee papers (PDF 1.09 MB)

  Published:

  03 August 2022